Answers are grounded in this paper and cite their sources.
Pleural mesothelioma is an aggressive malignancy, and nivolumab plus ipilimumab is the standard first-line treatment. We report the case of an 80-year-old man with advanced, unresectable pleural mesothelioma who was treated with nivolumab plus ipilimumab and developed grade 4 immune-mediated hepatitis. Immune checkpoint inhibitor therapy was permanently discontinued, and prednisolone treatment was initiated and gradually tapered over 5 months. A radiological complete response was confirmed by chest computed tomography and has persisted for approximately 2 years after permanent discontinuation of nivolumab plus ipilimumab. This case highlights the potential for a durable antitumor response to nivolumab plus ipilimumab in an elderly patient with unresectable pleural mesothelioma. Durable tumor control may persist even after permanent discontinuation of immune checkpoint inhibitor therapy and systemic corticosteroid treatment for grade 4 immune-mediated hepatitis.
No takes yet. Share an insight, caveat, or question.
Fujita et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: